Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Real-World Study of Percutaneous Pulmonary Artery Denervation (PADN) for the Treatment of Pulmonary Arterial Hypertension (PAH)

NCT07039604 is registered in ClinicalTrials.gov with Pulnovo Medical (Wuxi) Co., Ltd. as lead sponsor.

NCT NCT07039604
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07039604 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Real-World Study of Percutaneous Pulmonary Artery Denervation (PADN) for the Treatment of Pulmonary Arterial Hypertension (PAH)
Lead sponsor
Pulnovo Medical (Wuxi) Co., Ltd.
Phase
Observational
Overall status
Recruiting
Start date
March 19, 2025
Completion date
December 30, 2028
Enrollment
200 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hypertension, pulmonary arterial, pulmonary hypertension